Human Immunology Biosciences IPO

Human Immunology Biosciences, or HI-Bio, is a biotechnology company using human genetic and immunological research. With a mission to develop precise therapies for patients with immune-mediated diseases (IMDs), HI-Bio focuses on draining the cellular drivers of these diseases to grow their programs to other IMD indicators through clinical-stage programming and pipeline. Human Immunology Biosciences was founded by Travis Murdoch in 2021 and is headquartered in San Francisco, CA.

Register for Details

For more details on financing and valuation for Human Immunology Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Human Immunology Biosciences

Forge green plus iconForge green minus icon

Is Human Immunology Biosciences a publicly traded company?

Human Immunology Biosciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

Will Human Immunology Biosciences go IPO?

Human Immunology Biosciences has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

Forge green plus iconForge green minus icon

What is Human Immunology Biosciences's IPO price?

The IPO price for Human Immunology Biosciences will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Human Immunology Biosciences pre-IPO?

Human Immunology Biosciences is privately held company and is not publicly traded, therefor investing in Human Immunology Biosciences pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

Forge green plus iconForge green minus icon

What is the value of my Human Immunology Biosciences shares?

To determine the value of your Human Immunology Biosciences shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Human Immunology Biosciences shares. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Can you sell Human Immunology Biosciences before it goes public?

Yes, you can seek to sell shares in Human Immunology Biosciences while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

Forge green plus iconForge green minus icon

When was Human Immunology Biosciences founded?

Human Immunology Biosciences was founded in 2021.

Who are Human Immunology Biosciences's major investors?

Viking Global Investors
Arch Venture Partners
Alpha Wave Global
Arkin Holdings
Jeito
MorphoSys
Monograph Capital
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.